Thoma OM, Neurath M, Waldner M (2021)
Publication Type: Journal article, Review article
Publication year: 2021
Book Volume: 12
DOI: 10.3389/fphar.2021.757120
Cyclin-dependent kinases (CDKs) are key players in cell cycle regulation. So far, more than ten CDKs have been described. Their direct interaction with cyclins allow progression through G1 phase, transitions to S and G2 phase and finally through mitosis (M). While CDK activation is important in cell renewal, its aberrant expression can lead to the development of malignant tumor cells. Dysregulations in CDK pathways are often encountered in various types of cancer, including all gastrointestinal (GI) tract tumors. This prompted the development of CDK inhibitors as novel therapies for cancer. Currently, CDK inhibitors such as CDK4/6 inhibitors are used in pre-clinical studies for cancer treatment. In this review, we will focus on the therapeutic role of various CDK inhibitors in colorectal cancer, with a special focus on the CDK4/6 inhibitors.
APA:
Thoma, O.-M., Neurath, M., & Waldner, M. (2021). Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.757120
MLA:
Thoma, Oana-Maria, Markus Neurath, and Maximilian Waldner. "Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment." Frontiers in Pharmacology 12 (2021).
BibTeX: Download